FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134164486> ?p ?o ?g. }

• W2134164486 endingPage "2284" @default.
• W2134164486 startingPage "2279" @default.
• W2134164486 abstract "It has been proposed that the novel thrombolytic microplasmin may be useful in the treatment of ischemic stroke. In the present study the effects and safety profile of microplasmin were evaluated in 2 rabbit embolic stroke models that have been used successfully to develop tissue plasminogen activator (tPA) as the only Food and Drug Administration-approved treatment for stroke. The rabbit small clot embolic stroke model (RSCEM) and rabbit large clot embolic stroke model (RLCEM) were used to determine the potential neuroprotective properties and safety profile of microplasmin, respectively, after an embolic stroke.Rabbits were embolized by injecting small blood clots (RSCEM) or large blood clots (RLCEM) into the cerebral circulation. For the RSCEM, 126 rabbits were included, with behavioral analysis conducted 24 hours later, allowing for determination of the effective stroke dose (ES50) or clot amount (milligrams) that produces severe neurological deficits in 50% of rabbits. For RLCEM safety study analysis, 47 rabbits were included, with postmortem analyses consisting of assessment of hemorrhage and infarct rate and size. In test animals microplasmin was infused intravenously 60 minutes after embolization, whereas control rabbits were given infusions of the saline/Plasma-Lyte vehicle with all assessments performed in a blinded fashion.In the RSCEM, a drug is considered neuroprotective if it significantly increases the ES50 compared with the vehicle-treated control group. The ES50 of the vehicle-treated control group 24 hours after embolization was 1.36+/-0.42 mg (n=38). Microplasmin, infused starting 60 minutes after embolization, increased the ES50 to 2.32+/-0.57 (n=21), 1.89+/-0.48 (n=21), 2.81+/-0.55 (n=22), and 1.89+/-0.28 mg (n=24) for the 1-, 2-, 4-, and 8-mg/kg doses, respectively. There was a statistically significant behavioral improvement in the 4-mg/kg dose arm (P=0.040). The microplasmin dose of microplasmin that was statistically significant (4 mg/kg) was subsequently determined to be safe in the RLCEM because it did not increase the incidence of hemorrhages (56%) compared with vehicle-treated rabbits (63%), nor did it significantly alter hemorrhage volume, infarct rate, or infarct volume.The present study shows that microplasmin improves behavioral rating scores in the RSCEM when administered 60 minutes after embolization, at a dose that does not increase hemorrhages in the RLCEM. This is in contrast to tPA, which significantly enhances the hemorrhage rate in the RLCEM." @default.
• W2134164486 created "2016-06-24" @default.
• W2134164486 creator A5010690046 @default.
• W2134164486 creator A5016280147 @default.
• W2134164486 creator A5028934169 @default.
• W2134164486 creator A5041381739 @default.
• W2134164486 creator A5060081589 @default.
• W2134164486 creator A5086458434 @default.
• W2134164486 date "2002-09-01" @default.
• W2134164486 modified "2023-10-17" @default.
• W2134164486 title "Microplasmin: A Novel Thrombolytic That Improves Behavioral Outcome After Embolic Strokes in Rabbits" @default.
• W2134164486 cites W1846063887 @default.
• W2134164486 cites W1959023497 @default.
• W2134164486 cites W1968838122 @default.
• W2134164486 cites W1971854350 @default.
• W2134164486 cites W1981989118 @default.
• W2134164486 cites W2060771258 @default.
• W2134164486 cites W2070180187 @default.
• W2134164486 cites W2074463413 @default.
• W2134164486 cites W2077401978 @default.
• W2134164486 cites W2083268271 @default.
• W2134164486 cites W2088115137 @default.
• W2134164486 cites W2089506841 @default.
• W2134164486 cites W2128151087 @default.
• W2134164486 cites W2129598039 @default.
• W2134164486 cites W2144859488 @default.
• W2134164486 cites W2160720714 @default.
• W2134164486 cites W2292308933 @default.
• W2134164486 doi "https://doi.org/10.1161/01.str.0000028267.09604.7b" @default.
• W2134164486 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12215599" @default.
• W2134164486 hasPublicationYear "2002" @default.
• W2134164486 type Work @default.
• W2134164486 sameAs 2134164486 @default.
• W2134164486 citedByCount "97" @default.
• W2134164486 countsByYear W21341644862012 @default.
• W2134164486 countsByYear W21341644862013 @default.
• W2134164486 countsByYear W21341644862014 @default.
• W2134164486 countsByYear W21341644862016 @default.
• W2134164486 countsByYear W21341644862017 @default.
• W2134164486 countsByYear W21341644862018 @default.
• W2134164486 countsByYear W21341644862019 @default.
• W2134164486 countsByYear W21341644862020 @default.
• W2134164486 countsByYear W21341644862021 @default.
• W2134164486 countsByYear W21341644862022 @default.
• W2134164486 crossrefType "journal-article" @default.
• W2134164486 hasAuthorship W2134164486A5010690046 @default.
• W2134164486 hasAuthorship W2134164486A5016280147 @default.
• W2134164486 hasAuthorship W2134164486A5028934169 @default.
• W2134164486 hasAuthorship W2134164486A5041381739 @default.
• W2134164486 hasAuthorship W2134164486A5060081589 @default.
• W2134164486 hasAuthorship W2134164486A5086458434 @default.
• W2134164486 hasConcept C126322002 @default.
• W2134164486 hasConcept C127413603 @default.
• W2134164486 hasConcept C141071460 @default.
• W2134164486 hasConcept C164705383 @default.
• W2134164486 hasConcept C25498285 @default.
• W2134164486 hasConcept C2776035437 @default.
• W2134164486 hasConcept C2776572282 @default.
• W2134164486 hasConcept C2777377995 @default.
• W2134164486 hasConcept C2777397205 @default.
• W2134164486 hasConcept C2779581417 @default.
• W2134164486 hasConcept C2780645631 @default.
• W2134164486 hasConcept C2909817843 @default.
• W2134164486 hasConcept C2910003425 @default.
• W2134164486 hasConcept C3020199598 @default.
• W2134164486 hasConcept C42219234 @default.
• W2134164486 hasConcept C500558357 @default.
• W2134164486 hasConcept C541997718 @default.
• W2134164486 hasConcept C71924100 @default.
• W2134164486 hasConcept C78519656 @default.
• W2134164486 hasConcept C98274493 @default.
• W2134164486 hasConceptScore W2134164486C126322002 @default.
• W2134164486 hasConceptScore W2134164486C127413603 @default.
• W2134164486 hasConceptScore W2134164486C141071460 @default.
• W2134164486 hasConceptScore W2134164486C164705383 @default.
• W2134164486 hasConceptScore W2134164486C25498285 @default.
• W2134164486 hasConceptScore W2134164486C2776035437 @default.
• W2134164486 hasConceptScore W2134164486C2776572282 @default.
• W2134164486 hasConceptScore W2134164486C2777377995 @default.
• W2134164486 hasConceptScore W2134164486C2777397205 @default.
• W2134164486 hasConceptScore W2134164486C2779581417 @default.
• W2134164486 hasConceptScore W2134164486C2780645631 @default.
• W2134164486 hasConceptScore W2134164486C2909817843 @default.
• W2134164486 hasConceptScore W2134164486C2910003425 @default.
• W2134164486 hasConceptScore W2134164486C3020199598 @default.
• W2134164486 hasConceptScore W2134164486C42219234 @default.
• W2134164486 hasConceptScore W2134164486C500558357 @default.
• W2134164486 hasConceptScore W2134164486C541997718 @default.
• W2134164486 hasConceptScore W2134164486C71924100 @default.
• W2134164486 hasConceptScore W2134164486C78519656 @default.
• W2134164486 hasConceptScore W2134164486C98274493 @default.
• W2134164486 hasIssue "9" @default.
• W2134164486 hasLocation W21341644861 @default.
• W2134164486 hasLocation W21341644862 @default.
• W2134164486 hasOpenAccess W2134164486 @default.
• W2134164486 hasPrimaryLocation W21341644861 @default.
• W2134164486 hasRelatedWork W1978075191 @default.
• W2134164486 hasRelatedWork W1992000349 @default.

• next